SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel ...
VIR-5500 pairs PSMA targeting with CD3 engagement and PRO-XTEN masking intended to limit systemic T-cell activation until tumor-localized unmasking, potentially reducing off-tumor toxicity. Metastatic ...
Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumors New candidate APVO455 targets Nectin-4+ cancers, joins ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する